To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?
Wang
Peng-Hui
PH
Chao
Hsiang-Tai
HT
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003657:Decision Making; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015994:Incidence; D015412:Mastectomy, Segmental / Q000379:methods; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000517:prevention & control*; D011379:Prognosis; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D013629:Tamoxifen; D020849:Raloxifene Hydrochloride